| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
| Targets |
2-Amino-6-bromopyridine is a chemical intermediate. However, it has been identified as a ligand for the PqsR (Pseudomonas quinolone signal receptor) protein, a key transcriptional regulator of quorum sensing and virulence factor production in Pseudomonas aeruginosa. It binds to PqsR with a Kd of 6.8 uM in SPR assays and shows weak antagonistic activity. This makes it a starting point for developing anti-infective agents that block bacterial communication.
|
|---|---|
| ln Vitro |
2-Amino-6-bromopyridine (compound 7) is a PqsR ligand with a Kd value of 6.8 microM in a Surface Plasmon Resonance (SPR) assay. It shows weak antagonistic activity, meaning it can block the receptor‘s activation by its natural ligand (the Pseudomonas Quinolone Signal, PQS). This activity makes it a valuable chemical probe for studying Pseudomonas aeruginosa quorum sensing and a lead compound for designing more potent inhibitors of this virulence pathway. It also shows inhibitory effects on HIV-68 protease.
|
| ln Vivo |
No specific in vivo data is reported for 2-Amino-6-bromopyridine itself. As a weak PqsR antagonist and chemical intermediate, it is not typically administered directly to animals as a therapy. However, because it is used in the synthesis of JAK2 inhibitors and other drugs, its in vivo relevance is linked to the final drug molecules. It could potentially be used in mouse models of Pseudomonas aeruginosa infection to evaluate the role of PqsR in pathogenesis, though standard protocols would likely use more potent derivatives.
|
| Enzyme Assay |
Standard Surface Plasmon Resonance (SPR) assay for measuring ligand binding to PqsR. Recombinant PqsR protein is immobilized onto a CM5 sensor chip. 2-Amino-6-bromopyridine is prepared in running buffer (PBS, pH 7.4) at concentrations ranging from 0.1 to 100 microM. The compound is flowed over the chip. The association (ka) and dissociation (kd) rates are recorded. The equilibrium dissociation constant (Kd = 6.8 microM) is calculated. Positive and negative controls are used to validate the binding specificity.
|
| Cell Assay |
Standard PqsR antagonism cell-based assay. Pseudomonas aeruginosa reporter strains (e.g., PAO1 containing a pqsA-lux transcriptional reporter) are grown in LB medium. 2-Amino-6-bromopyridine is added to the culture at concentrations ranging from 1-500 uM. The natural PqsR agonist (PQS, 1-10 uM) is then added. After 4-6 hours of growth, bioluminescence (lux) or fluorescence is measured. The EC50 for the reduction of the reporter signal is calculated, indicating the compound‘s ability to block PqsR activation. No specific protocol for this compound is provided.
|
| Animal Protocol |
Not applicable. 2-Amino-6-bromopyridine is a research chemical used primarily as an intermediate, not a drug for efficacy studies. It could be used in a mouse model of acute pneumonia to study the role of PqsR. Mice (e.g., C57BL/6) are intranasally infected with Pseudomonas aeruginosa. 2-Amino-6-bromopyridine is administered intraperitoneally (e.g., 10-50 mg/kg) twice daily. Survival, bacterial burden in lungs, and levels of pro-inflammatory cytokines (TNF-alpha, IL-6) in bronchoalveolar lavage fluid are measured. However, such studies are rare due to its weak activity. No specific protocol is found.
|
| ADME/Pharmacokinetics |
Not applicable. 2-Amino-6-bromopyridine is a chemical intermediate, not a drug candidate. Pharmacokinetic (PK) properties are not reported. As a small molecule (MW 173.01), it is likely absorbed via passive diffusion. However, its primary utility is in chemical synthesis. In a drug discovery context, the PK of the final drug molecule (e.g., a JAK2 inhibitor) would be characterized, not the starting material. It is stored under standard conditions.
|
| Toxicity/Toxicokinetics |
2-Amino-6-bromopyridine is a chemical intermediate and irritant. No specific toxicological data (LD50) is provided. It may cause skin and eye irritation. It should be handled with care: wear gloves, goggles, and lab coat. Avoid inhalation of dust. It is not intended for human consumption. It is generally stable but should be stored in a cool, dry, well-ventilated area away from strong oxidizing agents. For research use only. Not for drug, household, or other uses.
|
| References | |
| Additional Infomation |
2-Amino-6-bromopyridine (CAS: 19798-81-3) has a molecular formula of C5H5BrN2 and a molecular weight of 173.01. Its IUPAC name is 6-bromopyridin-2-amine. It is a white to pale yellow crystalline powder. Its purity is typically ≥ 99%. It is used as a preservative and disinfectant. It can also be used as a corrosion inhibitor. Due to the bromine atom, it is a reactive intermediate for Suzuki-Miyaura and Buchwald-Hartwig cross-coupling reactions. For research use only. Each product in one row, fields tab-separated.
|
| Molecular Formula |
C5H5BRN2
|
|---|---|
| Molecular Weight |
173.01
|
| Exact Mass |
171.964
|
| CAS # |
19798-81-3
|
| PubChem CID |
300809
|
| Appearance |
Typically exists as solids at room temperature
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
273.0±20.0 °C at 760 mmHg
|
| Melting Point |
88-91 °C(lit.)
|
| Flash Point |
118.9±21.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.636
|
| LogP |
1.81
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
76.8
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1=CC=CC(N)=N1
|
| InChi Key |
BKLJUYPLUWUEOQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H5BrN2/c6-4-2-1-3-5(7)8-4/h1-3H,(H2,7,8)
|
| Chemical Name |
6-bromopyridin-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.7800 mL | 28.9001 mL | 57.8001 mL | |
| 5 mM | 1.1560 mL | 5.7800 mL | 11.5600 mL | |
| 10 mM | 0.5780 mL | 2.8900 mL | 5.7800 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
